star performer

Good to see this exciting little biotech, ticking all the boxes, good management, good board, and sales increasing in the US, Europe and worldwide. It will be interesting to see their next half yearly sales figures which are continually rising. Most importantly they have a strong balance sheet, and their technology is getting smaller and less evasive. Seems to me they the thrombosis issue well under control now which was hyped up by their competitors.. Heading towards full FDA approval next year.. Look forwarding to this potentially being more than Cochlear one day.. Well Done Heartware..